GRASSO MARC 4

What Happened

• Marc Grasso, Chief Financial Officer of Kyverna Therapeutics (KYTX), received equity awards on March 13, 2026: 10,000 restricted stock units (RSUs) and a 65,000-share option award (reported as a derivative). Both grants show $0.00 as the acquisition price on the Form 4 (i.e., these are company awards, not open‑market purchases).

Key Details

• Transaction date: March 13, 2026; Form 4 filed March 17, 2026 (filing appears timely).
• Awards: 10,000 RSUs (@ $0.00) and 65,000 derivative shares (option award) (@ $0.00).
• Vesting (per footnotes): RSUs — 1/4 vest on March 13, 2027 and 1/4 each year thereafter; Options — 1/4 vest on March 13, 2027 and then 1/48 each month thereafter, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Transaction code: A = Award/Grant; derivative entry indicates an option grant (not an exercise or sale).

Context

• These are compensatory equity grants (awards), not purchases or sales, and do not indicate immediate cash proceeds. The option award is a derivative security subject to vesting; it was granted, not exercised. Such grants are common for executive compensation and are contingent on continued service and future vesting.